GlassScriptPhysician profile
Ritu Anand
NPI 1255353512
$2,800.58
in general payments reported to CMS, 2019-2025
32 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $642 · 2021: $319 · 2024: $184 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $516.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $303.88 | 2019-2021 | |
| Corcept Therapeutics | $236.72 | 2019-2025 | Korlym |
| Davol INC. | $218.23 | 2025 | Phasix Mesh, Arista, Bard 3dmax Mesh |
| Mannkind Corporation | $214.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $193.90 | 2019-2021 | |
| Medtronic, INC. | $107.53 | 2024 | Percept PC Brainsense |
| Lilly USA, LLC | $90.73 | 2019-2025 | Zepbound, Mounjaro |
| Amneal Pharmaceuticals LLC | $90.58 | 2024-2025 | Unithroid |
| Abbvie INC. | $75.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.67 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $69.18 | 2019-2021 | |
| Pfizer INC. | $56.98 | 2019-2020 | |
| Amgen INC. | $55.61 | 2025 | Tepezza |
| Currax Pharmaceuticals LLC | $55.21 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $51.65 | 2020-2021 | |
| Topcon Healthcare Solutions, INC. | $49.91 | 2020 | |
| Ibsa Pharma INC. | $40.87 | 2019-2021 | |
| Eisai INC. | $38.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.90 | 2020 | |
| Amarin Pharma, INC. | $26.88 | 2019-2021 | |
| Convatec INC. | $26.75 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $26.52 | 2019 | |
| Dexcom, INC. | $21.38 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $21.00 | 2019 | |
| Conmed Corporation | $20.51 | 2025 | Airseal |
| Madrigal Pharmaceuticals | $19.54 | 2025 | Rezdiffra |
| Ethicon US, LLC | $18.66 | 2025 | Vistaseal |
| Becton, Dickinson and Company | $14.47 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.84 | 2024 | Dsuvia |
| Alexion Pharmaceuticals, INC. | $11.80 | 2020 | |
| Insulet Corporation | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.